Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments (2016 - 2025)

Enanta Pharmaceuticals' Short-term Investments history spans 14 years, with the latest figure at $148.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 24309.87% year-over-year to $148.4 million; the TTM value through Dec 2025 reached $148.4 million, up 24309.87%, while the annual FY2025 figure was $156.6 million, 25.78% down from the prior year.
  • Short-term Investments reached $148.4 million in Q4 2025 per ENTA's latest filing, down from $156.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $298.8 million in Q1 2021 to a low of $608000.0 in Q4 2024.
  • Average Short-term Investments over 5 years is $203.0 million, with a median of $205.2 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: plummeted 99.8% in 2024, then soared 24309.87% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then surged by 72.55% to $297.2 million in 2023, then tumbled by 99.8% to $608000.0 in 2024, then skyrocketed by 24309.87% to $148.4 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Short-term Investments are $148.4 million (Q4 2025), $156.6 million (Q3 2025), and $159.3 million (Q2 2025).